Actively Recruiting
Evaluating Intravenous Vedolizumab for Treatment of Moderate to Severe Crohns Disease in Adults in China A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Led by Takeda · Updated on 2026-11-02
408
Participants Needed
43
Research Sites
64 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and activity of vedolizumab intravenous infusion as a treatment for adults in China with moderately to severely active Crohns Disease. This phase 3 study involves about 408 participants and compares vedolizumab with a placebo during a 14-week induction period. The study aims to assess clinical response and remission, as well as endoscopic response, to understand how vedolizumab works for this condition. Participants will receive vedolizumab 300 mg intravenous infusions at Weeks 0, 2, and 6 during the induction period, or placebo infusions on the same schedule. After Week 14, all participants continue in an open-label extension period receiving vedolizumab every 8 weeks. From Week 18 onward, those who do not respond well or whose disease worsens may receive vedolizumab every 4 weeks. This treatment phase lasts about 58 weeks. During the study, participants will attend up to 20 visits for assessments including clinical evaluations, endoscopic exams, and safety monitoring. Researchers will track clinical response, remission, adverse events, laboratory results, and vital signs through Week 14 and up to 18 weeks after the last dose. A final safety follow-up occurs 18 weeks after the last dose, and a long-term safety survey is conducted six months later via telephone. Overall, participants will be involved in the study for approximately 58 weeks plus follow-up periods.
CONDITIONS
Brief Title
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here